HLB Pharmaceutical Co. Ltd (047920) — Capital Reinvestment Ratio
HLB Pharmaceutical Co. Ltd (047920) has a Capital Reinvestment Ratio of 1.21x as of September 2025, meaning it reinvests 1% of its operating cash flow (₩1.86 Billion) in capital expenditures (₩2.26 Billion). See HLB Pharmaceutical Co. Ltd balance sheet quality to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
HLB Pharmaceutical Co. Ltd Capital Reinvestment Ratio (2014–2024)
This chart tracks HLB Pharmaceutical Co. Ltd's Capital Reinvestment Ratio across 3 annual periods. Check total reinvestment intensity of HLB Pharmaceutical Co. Ltd to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for HLB Pharmaceutical Co. Ltd (2014–2024)
Year-by-year Capital Reinvestment Ratio for HLB Pharmaceutical Co. Ltd from 2014 to 2024. For live market cap and broader valuation context, see HLB Pharmaceutical Co. Ltd market cap and net worth.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.45x | ₩6.84 Billion | ₩3.09 Billion | ▼ -56.2% |
| 2019 | 1.03x | ₩1.35 Billion | ₩1.40 Billion | ▼ -29.6% |
| 2014 | 1.47x | ₩1.54 Billion | ₩2.26 Billion | — |